Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | AHR | P35869 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | HTR6 | P50406 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arundine SCHEMBL325162 | 0.78 | MEN1 (1.00) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL16431196 | 0.78 | GPR84 (0.69) | GPR84MEN1KMT2ACYP3A4MAPT | |
| Arundine SCHEMBL28335217 | 0.77 | MEN1 (0.95) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL31744758 | 0.75 | GPR84 (0.65) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL735576 | 0.75 | GPR84 (0.65) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL2854051 | 0.75 | HSPA5 (0.52) | CYP2D6MPOCYP1A2TAAR1TSHR | |
| SCHEMBL12559876 | 0.73 | GPR84 (0.61) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL9219681 | 0.73 | GPR84 (0.61) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL17179343 | 0.73 | GPR84 (0.61) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL469685 | 0.73 | KDM4E (0.41) | CYP3A4ALDH1A1KDM4ECYP1A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8168634-B2 | Thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| EP-2084155-A1 | THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071888-A1 | PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008047109-A1 | THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | GPR84 2236/4885MEN1 1461/4885KMT2A 2966/4885 |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | TEC, BTK, PI4KA | GPR84 2281/4885MEN1 1425/4885KMT2A 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.